HRT Financial’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

HRT Financial’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,470	Closed	-$48K	–	4015
2022 Q1	$48K	Buy	+14,470	New	+$45.9K	﹤0.01%	2754
2021 Q4	–	Sell	-68,379	Closed	-$223K	–	4370
2021 Q3	$223K	Sell	68,379 -17,704	-21%	-$62K	﹤0.01%	2611
2021 Q2	$363K	Buy	+86,083	New	+$364K	﹤0.01%	2025
2020 Q1	–	Sell	-16,627	Closed	-$153K	–	1497
2019 Q4	$153K	Buy	+16,627	New	+$118K	0.01%	981

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

HRT Financial's CNCE Position: Q2 2022 in Review

HRT Financial sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2022, closing a stake of 14,470 shares — an estimated $48K sold.

HRT Financial first reported a position in CNCE in Q4 2019 and held it in 4 quarters. The position peaked at $363K in Q2 2021. 70 funds tracked by Wall St. Rank hold CNCE as of Q2 2022.

HRT Financial reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
HRT Financial sold 14,470 Concert Pharmaceuticals, Inc. shares in Q2 2022, an estimated $48K.
HRT Financial first reported a position in Concert Pharmaceuticals, Inc. in Q4 2019 and held it in 4 quarters.
HRT Financial's Concert Pharmaceuticals, Inc. position peaked at $363K in Q2 2021.
70 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2022.

Based on HRT Financial's 13F filing for Q2 2022, filed 12 Aug 2022.